Table 2. Medications.
| Variables | All (n = 483) | ASCVD (n = 195) | Non-ASCVD (n = 288) | P value |
|---|---|---|---|---|
| Anti-hypertension | ||||
| ARB/ACE-I, n (%) | 237 (49) | 125 (64) | 112 (39) | < 0.001 |
| CCB, n (%) | 233 (48) | 114 (59) | 119 (41) | < 0.001 |
| Beta-blocker, n (%) | 61 (13) | 35 (18) | 26 (9) | 0.004 |
| Others, n (%) | 74 (15) | 40 (21) | 34 (12) | 0.01 |
| Anti-diabetes | ||||
| DPP-4I, n (%) | 77 (16) | 40 (21) | 37 (13) | 0.02 |
| Others, n (%) | 60 (12) | 34 (17) | 26 (9) | 0.006 |
| Anti-dyslipidemia | ||||
| Statin, n (%) | 239 (50) | 128 (66) | 111 (39) | < 0.001 |
| EPA, n (%) | 57 (12) | 35 (18) | 22 (8) | < 0.001 |
| Others, n (%) | 29 (6) | 12 (6) | 17 (6) | 0.9 |
P value shows the comparison with ASCVD vs. non-ASCVD. ASCVD: atherosclerotic cardiovascular disease; ARB: angiotensin II receptor blocker; ACE-I: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker; EPA: eicosapentaenoic acid; DPP-4I: dipeptidyl peptidase-4 inhibitor.